Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4755-4765

  Attar Schneider, Oshrat ^a,b   Zismanov, Victoria ^a,b   Drucker, Liat ^a,b   Gottfried, Maya ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

eIF4E eIF4GI; Human mesenchymal stem cells; Migration; NSCLC; Translation initiation

Indexed keywords

EUKARYOTIC TRANSLATION INITIATION FACTOR 4GI; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE; SECRETOME; SECRETORY PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; EIF4ENIF1 PROTEIN, HUMAN; EIF4G1 PROTEIN, HUMAN; INITIATION FACTOR 4G; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PROTEOME;

AGED; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER GROWTH; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; CANCER STEM CELL; CELL MOTION; CELL SURVIVAL; DISEASE COURSE; LUNG TUMOR; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TRANSLATION INITIATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4G; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESENCHYMAL STROMAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASTIC STEM CELLS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PROTEOME;

EID: 84945549829     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4304-3     Document Type: Article

References (49)

1. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117:2740–50.
2. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther. 2009;9:1365–78.
3. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007;67:11300–8.
4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.
5. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–63.
6. Liu R, Wei S, Chen J, Xu S. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett. 2014;353:145–52.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
8. Korkaya H, Wicha MS. Breast cancer stem cells: we’ve got them surrounded. Clin Cancer Res. 2013;19:511–3.
9. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyllaki M, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010;19:1043–54.
10. Gottschling S, Granzow M, Kuner R, Jauch A, Herpel E, Xu EC, et al. Mesenchymal stem cells in non-small cell lung cancer—different from others? Insights from comparative molecular and functional analyses. Lung Cancer. 2013;80:19–29.
11. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006;198:54–64.
12. Kim S, Kim HS, Lee E, Kim HO. In vivo hepatic differentiation potential of human cord blood-derived mesenchymal stem cells. Int J Mol Med. 2011;27:701–6.
13. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10:254–66.
14. Barnhart B, Simon M. Taking aim at translation for tumor therapy. J Clin Invest. 2007;117:2385–8.
15. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med. 2003;81:536–48.
16. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007;136:565–73.
17. Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272–80.
18. Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E. Overexpression of the eukaryotic translation initiation factor 4G (EIF4G-1) in squamous cell lung carcinoma. Int J Cancer. 2002;98:181–5.
19. Zismanov V, Drucker L, Gottfried M. ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors. Pulm Pharmacol Ther. 2013;26:388–94.
20. Zismanov V, Drucker L, Gottfried M. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration. Anti Cancer Drugs. 2014;25:998–1006.
21. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther. 2002;1:971–9.
22. Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 2006;66:4256–62.
23. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments trail-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia. 2010;12:346–56.
24. Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H, Drucker L. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer. 2009;101:1402–9.
25. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Investig. 2012;92:178–90.
26. O’Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 2008;409:635–49.
27. Dolfi SC, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 2013;1:20.
28. Zismanov V, Drucker L, Attar-Schneider O, Matalon ST, Pasmanik-Chor M, Lishner M. Tetraspanins stimulate protein synthesis in myeloma cell lines. J Cell Biochem. 2012;113:2500–10.
29. Robert F, Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets. 2009;13:1279–93.
30. Yang YJ, Zhang YL, Wang JD, Lai ZS, Wang QY, Cui HH. [Role of eukaryotic initiation factor-4E (eIF-4E) in regulation of expression of NF-kappaB and its subsequent influence on transcription and activity of heparanase in human colon adenocarcinoma cell line]. Ai Zheng. 2003;22:1023–9.
31. Shiroki K, Ohsawa C, Sugi N, Wakiyama M, Miura K, Watanabe M, et al. Internal ribosome entry site-mediated translation of Smad5 in vivo: requirement for a nuclear event. Nucleic Acids Res. 2002;30:2851–61.
32. Baird SD, Turcotte M, Korneluk RG, Holcik M. Searching for IRES. RNA. 2006;12:1755–85.
33. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28:501–12.
34. Kaiser C, Dobrikova EY, Bradrick SS, Shveygert M, Herbert JT, Gromeier M. Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. RNA. 2008;14:2170–82.
35. Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013;8:e59083.
36. Shveygert M, Kaiser C, Bradrick SS, Gromeier M. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol Cell Biol. 2010;30:5160–7.
37. Ampollini L, Madeddu D, Falco A, Frati C, Lorusso B, Graiani G, et al. Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cellsdagger. Eur J Cardiothorac Surg. 2014;46:e103–12.
38. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.
39. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 2011;6:576–82.
40. Roato I. Bone metastases: when and how lung cancer interacts with bone. World J Clin Oncol. 2014;5:149–55.
41. Campolo F, Gori M, Favaro R, Nicolis S, Pellegrini M, Botti F, et al. Essential role of Sox2 for the establishment and maintenance of the germ cell line. Stem Cells. 2013;31:1408–21.
42. Fernandez Vallone VB, Hofer EL, Choi H, Bordenave RH, Batagelj E, Feldman L, et al. Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. Clin Exp Metastasis. 2013;30:317–32.
43. Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates and marks cancer progression. Semin Cancer Biol. 2014;28:14–23.
44. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci. 2014;15:4142–57.
45. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 2013;8:e84256.
46. Attar-Schneider O, Zismanov V, Dabbah M, Tartakover-Matalon S, Drucker L, Lishner M. Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: effect on translation initiation. Mol Carcinog. 2015. doi:10.1002/mc.22378.
47. Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7:e35685.
48. Nasr Z, Pelletier J. Tumor progression and metastasis: role of translational deregulation. Anticancer Res. 2012;32:3077–84.
49. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010;70:3780–90.